SCHEMBL16338237

SCHEMBL16338237

CC(C)(C)OC(=O)N1CC[C@@H](C(F)F)C1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.48
DPP4 P27487 1/20 0.47
RECQL P46063 1/20 0.46
EPHX1 P07099 1/20 0.46
GPR119 Q8TDV5 8/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16338236 1.00 HPGD (0.48) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL23523667 1.00 HPGD (0.48) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL28600836 0.91 ALDH1A1 (0.51) HPGDDPP4RECQLEPHX1ALDH1A1
SCHEMBL26709621 0.91 ALDH1A1 (0.51) HPGDDPP4RECQLEPHX1ALDH1A1
SCHEMBL2706672 0.90 HPGD (0.54) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL10190233 0.86 NR1H2 (0.50) HPGDDPP4RECQLEPHX1ALDH1A1
SCHEMBL21645191 0.86 GPR119 (0.45) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL25341769 0.86 GPR119 (0.45) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL4546635 0.85 HPGD (0.49) HPGDDPP4RECQLEPHX1GPR119
SCHEMBL21316612 0.85 HPGD (0.49) HPGDDPP4RECQLEPHX1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175043-A1 PYRIDOPYRIMIDINE DERIVATIVE AND USE THEREOF 广东东阳光药业股份有限公司 2024-08-29 WO disclosed
EP-2791133-B1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2019-04-17 EP disclosed
EP-2791133-B1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2019-04-17 EP disclosed
US-9193714-B2 Fluorinated estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2015-11-24 US disclosed
US-9193714-B2 Fluorinated estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2015-11-24 US disclosed
US-9193714-B2 Fluorinated estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2015-11-24 US disclosed
US-20150005286-A1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-01-01 US disclosed
US-20150005286-A1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-01-01 US disclosed
US-20150005286-A1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005286-A1 FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF GPER1, ESR2, ESRRG HPGD 675/4885DPP4 2010/4885RECQL 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.